The inclusion of glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist-based medications has been very successful for the treatment of type 2 diabetes (T2D) and obesity (Aronne et al, 2024; Gallwitz, 2022; Kusminski et al, 2024; Lyons and Beaudry, 2023; Müller et al, 2025). Here, GIPR is linked to obesity due to melanocortin 4 receptor deficiency.